Quarterly report pursuant to Section 13 or 15(d)

Shareholders Equity (Details Textual)

v3.20.1
Shareholders Equity (Details Textual)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 25, 2020
Employees
$ / shares
shares
Oct. 28, 2019
shares
Mar. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
Employees
consultants
$ / shares
shares
Nov. 30, 2017
shares
May 31, 2017
$ / shares
shares
Shareholders Equity (Textual)            
Common stock, authorized     60,000,000 60,000,000    
Common stock, par value | $ / shares     $ 0.0001      
Common stock, issued     22,925,860 22,925,860    
Common stock, shares outstanding     22,920,160 22,862,835    
Preferred stock, par value | $ / shares     $ 0.0001      
Preferred stock, shares authorized     1,000,000      
Grant options | $ / shares     $ 914,741      
Equity incentive plan, description     There are 101,041 shares available for issuance under the plan      
Fair value granted | $     $ 3,600      
Issuance of warrants     236,552      
Warrants, description     a. 177,414 upon the filing of a patent application covering any Discovered Target or a Product b. 118,277 upon achievement of the earlier of the following milestone by the Company: (i) execution of an agreement with a pharmaceutical company with respect to the commercialization of any of the Company’s licensed technology or the Consulting IP or a Product (both defined in the 2017 License Agreement) or (ii) the filing of a patent application covering any Discovered Target (as defined in the 2017 License Agreement) or a Product. c. 59,139 upon completion of a Phase 1 clinical trial in respect of a Product.      
Public warrants, description     ● in whole and not in part; ● at a price of $0.01 per warrant; ● at any time during the exercise period; ● upon a minimum of 30 days’ prior written notice of redemption; ● if, and only if, the last sale price of the Company’s common stock equals or exceeds $16.00 per share for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders; and ● if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.      
Warrants expire years     5 years      
Common Stock            
Shareholders Equity (Textual)            
Common stock, shares outstanding     22,920,160      
Yeda [Member]            
Shareholders Equity (Textual)            
Shares of issued warrants         7,615  
Founder [Member]            
Shareholders Equity (Textual)            
Shares of issued warrants         2,974  
License Agreement [Member]            
Shareholders Equity (Textual)            
Price Per Share | $ / shares           $ 0.0001
Warrants to purchase Ordinary Shares           591,382
New Incentive Plan [Member]            
Shareholders Equity (Textual)            
Common stock, par value | $ / shares       $ 0.0001    
Grant options | $ / shares       $ 1,000    
Equity incentive plan, description       The aggregate number of shares of Common Stock that may be delivered pursuant to the 2019 Plan will automatically increase on January 1 of each year, commencing on January 1, 2020 and ending on (and including) January 1, 2029, in an amount equal to four percent (4%) of the total number of Common Stock outstanding on December 31 of the preceding calendar year. Notwithstanding the foregoing, the Board of Directors may act prior to January 1 of a given year to provide that there will be no January 1 increase for such year or that the increase for such year will be a lesser number of Common Stock than provided herein.    
Stock Options [Member]            
Shareholders Equity (Textual)            
Purchase of ordinary shares       74,581    
Grant options | $ / shares       $ 527,716    
Grant approved 814,700     704,669    
Employees consideration | Employees 65     22    
Non-tradable options       79,630    
Consideration consultants | consultants       2    
Exercise price | $ / shares $ 6.21     $ 1.34    
BiomX Israel [Member]            
Shareholders Equity (Textual)            
Exchange for common shares   15,069,058        
Shares outstanding, percentage   65.00%        
Earnout shares, description       A. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2022 is greater than or equal to $16.50 per share. B. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2024 is greater than or equal to $22.75 per share. C. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2026 is greater than or equal to $29.00 per share.    
Purchase of ordinary shares       1    
Purchase common Stock share       1